Strategic Partners Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jakob Bendtsen

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	14.4%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	1.4yrs

Recente managementupdates

Recent updates

CEO

Jakob Bendtsen (46 yo)

less than a year

Tenure

Mr. Jakob F rch Bendtsen serves as Chief Executive Officer at Strategic Partners A/S (formerly known as Orphazyme A/S) since October 01, 2023. He was Director of Rovsing A/S from 2022 until 2024.He serves...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jakob Bendtsen	CEO & Director	1.4yrs	geen gegevens	14.44% € 765.8k
Michael Schlomo Hove	Independent Chairman	1.4yrs	geen gegevens	13.14% € 696.9k
Jakob Have	Independent Director	1.4yrs	geen gegevens	13.14% € 696.9k

1.4yrs

Gemiddelde duur

46yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1TB0 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.4 jaar), wat duidt op een nieuw bestuur.

Strategic Partners Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

No independent directors

Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO

Orphazyme A/S Announces Board Changes

Orphazyme A/S Announces Board Appointment

Orphazyme A/S Announces Executive Changes

Orphazyme A/S, Annual General Meeting, May 21, 2022

Recent updates

New major risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Financial data availability

No independent directors

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO

Orphazyme A/S Announces Board Changes

Orphazyme A/S to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Orphazyme A/S Revises Earnings Guidance for the Year 2022

Orphazyme American Depositary Shares - Sponsored to Be Deleted from Other OTC

Orphazyme A/S Announces Board Appointment

Orphazyme A/S Provides Earnings Guidance for the Full Year of 2022

KemPharm Denmark A/S acquired Substantially All Assets and Business Activities of Orphazyme A/S for $18 million.

Orphazyme A/S Announces Executive Changes

Orphazyme A/S(CPSE:ORPHA) dropped from S&P Global BMI Index

Orphazyme A/S announced delayed amended 20-F filing

Orphazyme A/S announced delayed 20-F filing

Orphazyme A/S to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Orphazyme A/S, Annual General Meeting, May 21, 2022

Forecast to breakeven in 2024

Orphazyme A/S Announces Update on Regulatory Review of Arimoclomol in the European Union

Orphazyme A/S Elects Andrew Mercieca as Member of the Board of Directors

Orphazyme Provides Update for Planned NDA Resubmission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the United States

Orphazyme to Present Additional Data on Arimoclomol’s Mechanism of Action During 2022 Annual Worldsymposium™

Orphazyme A/S Announces CEO Changes

Orphazyme A/S Revises Earnings Guidance for the Year 2021

Forecast to breakeven in 2024

Orphazyme A/S Maintains its Outlook for the Full Year 2021

Orphazyme A/S Announces Publication of Results from Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C in the Journal of Inherited Metabolic Disease

Independent Director Martijn Kleijwegt has left the company

Independent Director Remi P. Droller has left the company

Independent Director Anders Hedegaard has left the company

CytRx Corporation Announces 24-Month Interim Results of an Open-Label Extension Trial of Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Orphazyme Provides Earnings Guidance for the Year of 2021

Orphazyme A/S Announces Topline Data from Pivotal Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

Independent Director has left the company

Orphazyme A/S Appoints Christophe Bourdon as Chief Executive Officer, Effective on April 1, 2021

Orphazyme A/S to Showcase Data on Arimoclomol in Niemann-Pick Disease Type C During the 2021 Annual Worldsymposium™

New 90-day high: €10.56

CytRx Corporation Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C

Orphazyme A/S Announces the U.S. Food and Drug Administration Has Extended the Review Period of the New Drug Application

New 90-day low: €7.41

Orphazyme A/S Announces Executive Changes

Orphazyme A/S, Annual General Meeting, Mar 25, 2021

Orphazyme A/S to Report First Half, 2021 Results on Aug 24, 2021

Orphazyme A/S Submits European Marketing Authorisation Application for Arimoclomol for Treatment of Niemann-Pick Disease Type C

CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol

New 90-day low: €8.67

Orphazyme A/S has completed a Follow-on Equity Offering in the amount of $83.777606 million.

Orphazyme A/S Provides Update on Previously Announced Global Offering

New 90-day low: €9.92

Orphazyme A/S Elects Carrolee Barlow as Board of Director

New 90-day low - €11.52

CEO

Tenure

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd